Platinum agents

What it is

Platinum agents are cancer chemotherapy drugs, including cisplatin, carboplatin, and oxaliplatin, that damage tumour DNA. They are among the most widely used cytotoxic drug classes in oncology and are part of treatment for cancers such as testicular, ovarian, lung, bladder, head and neck, gastric, and colorectal cancers. The most important practical fact is that the class has three main commonly used drugs in routine care, and each has a different toxicity pattern, so they are not interchangeable in every setting.

These medicines are called platinum compounds because they contain the metal platinum in a chemical form that can react inside cells. In India, platinum-based chemotherapy is used across government and private cancer centres and is included in many standard regimens for solid tumours. A platinum drug may be given alone, with other chemotherapy, with radiation, or with immunotherapy depending on the cancer type and stage.

A simple comparison is below:

Drug	Common uses	Key toxicity pattern
Cisplatin	Testicular, bladder, head and neck, lung, cervical and other solid tumours	Kidney injury, hearing loss, nerve damage, severe nausea/vomiting
Carboplatin	Ovarian, lung and many combination regimens	More bone marrow suppression, especially low platelets; less kidney toxicity than cisplatin
Oxaliplatin	Colorectal and some gastric cancers	Peripheral neuropathy, often triggered or worsened by cold

How it works

Platinum agents enter cancer cells and become chemically activated, especially in the lower-chloride environment inside the body. The activated drug binds to DNA and forms cross-links, which distort the DNA structure and interfere with replication and transcription. When the damage is extensive, the cell may stop dividing and undergo programmed cell death.

Although this is the core mechanism, platinum drugs also affect RNA, proteins, oxidative stress pathways, and the tumour microenvironment. Their effects are not limited to cancer cells, which is why normal fast-dividing tissues and sensitive organs can also be injured. That explains many of the class toxicities, including low blood counts, nausea, neuropathy, kidney injury, and hearing damage.

The three main agents differ in chemistry and behavior:

1. Cisplatin is highly active in many tumours but is also the most strongly linked with nephrotoxicity and ototoxicity.
2. Carboplatin was developed to reduce some cisplatin toxicities; dosing is commonly individualised using kidney function.
3. Oxaliplatin has a different carrier ligand and is active in colorectal cancer, where cisplatin is not used in the same way.

Evidence and uses

Platinum chemotherapy has been a foundation of cancer treatment for decades. Cisplatin-based therapy transformed outcomes in some cancers, especially testicular cancer, and platinum combinations remain standard first-line treatment in many solid tumours. Modern regimens often combine a platinum drug with fluoropyrimidines, taxanes, gemcitabine, pemetrexed, etoposide, radiation, or immune checkpoint inhibitors.

Common settings where platinum agents are used include:

• Curative treatment: for example, testicular cancer, some head and neck cancers, cervical cancer, and certain lung cancers.
• Adjuvant or perioperative treatment: after or around surgery in selected lung, gastric, bladder, and other cancers.
• Palliative treatment: to shrink tumours, relieve symptoms, and prolong survival in advanced disease.
• Chemoradiation: cisplatin is often used as a radiosensitiser.

Evidence is strongest for approved drugs and established regimens. There is also active research on newer platinum compounds, platinum(IV) prodrugs, nanoparticles, and combination strategies to overcome resistance, but many of these approaches are still experimental and not standard care.

A major clinical issue is platinum resistance. Some cancers do not respond from the start, while others become resistant after initial benefit. Mechanisms include reduced drug uptake, increased drug inactivation, better DNA repair, and failure of cancer cells to undergo apoptosis. In practice, this means a patient may need a different platinum drug, a non-platinum regimen, targeted therapy, immunotherapy, or a clinical trial depending on the tumour type and prior response.

Safety and interactions

Platinum agents can cause serious side effects and require close monitoring by an oncology team. The exact risks depend on the drug, dose, schedule, prior treatment, age, kidney function, hearing status, and other illnesses.

Important safety issues include:

• Kidney injury: especially with cisplatin. Hydration and kidney function monitoring are standard.
• Low blood counts: especially with carboplatin, which can lower platelets, white cells, and haemoglobin.
• Peripheral neuropathy: common with oxaliplatin and cisplatin; oxaliplatin can cause acute cold-triggered tingling or throat discomfort.
• Hearing loss: cisplatin can damage hearing, sometimes permanently.
• Severe nausea and vomiting: cisplatin is highly emetogenic and usually needs strong anti-nausea prevention.
• Allergic or hypersensitivity reactions: these can occur, sometimes after multiple prior cycles, and may be severe.

Drug interactions matter. Other medicines that can harm the kidneys, ears, or nerves may increase toxicity. Examples include some aminoglycoside antibiotics, loop diuretics in certain contexts, and other neurotoxic chemotherapy drugs. Patients should tell their oncologist and pharmacist about all prescription drugs, over-the-counter medicines, and supplements. Herbal products and traditional remedies are not automatically safe during chemotherapy because they may affect liver enzymes, hydration, bleeding risk, or adherence.

Platinum drugs are given under specialist supervision. Patients should not try to manage side effects on their own if they have fever, reduced urine, severe vomiting, breathing symptoms during infusion, or rapidly worsening numbness.

When to see a clinician

Contact the treating team urgently if any of these happen during or after platinum chemotherapy:

• Fever of 38°C or higher
• Very little urine, swelling, or sudden weight gain
• Severe vomiting or inability to keep fluids down
• New hearing changes, ringing in the ears, or dizziness
• Numbness, burning pain, trouble buttoning clothes, or difficulty walking
• Rash, wheezing, chest tightness, or facial swelling during infusion
• Unusual bleeding or bruising

Patients receiving cisplatin or carboplatin usually need regular blood tests, including kidney function and blood counts. Some patients also need magnesium monitoring, hearing assessment, or dose adjustment based on renal function. In India, supportive care access can vary by centre, so patients should ask in advance about hydration, antiemetics, and emergency contact pathways.

Limitations and open questions

Platinum agents are effective, but they are limited by toxicity and resistance. Not every tumour that is called "platinum-sensitive" stays sensitive over time, and there is no single test that perfectly predicts who will benefit most or who will develop severe side effects.

Research is ongoing to identify biomarkers of response and resistance, reduce kidney and nerve toxicity, and improve desensitisation for hypersensitivity reactions. Newer platinum formulations and combinations are promising, but many remain early-stage or investigational. Evidence in humans is still limited for several next-generation platinum strategies discussed in laboratory and translational research.

For patients and families, the key point is that platinum chemotherapy is a standard and often effective treatment class, but the choice of agent depends on the cancer type, treatment goal, kidney function, prior exposure, and side-effect risks.